Brand Name :
Entyvio
Synonyms :
vedolizumab
Class :
Gastrointestinal agent & monoclonal antibody
Dosage Forms & Strengths
Solution reconstituted, Intravenous:
300 mg
Solution Prefilled syringe, Subcutaneous:
108 mg/0.68 ml
No safe and efficacious dosing indicated
Refer to adult dosing
may increase the risk or severity of adverse effects when combined
may decrease the diagnostic effect of each other when combined
may decrease the therapeutic effect of anticholinergic agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
it may reduce the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
anti-cholinergic agents may diminish the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
anticholinergic agents decrease the efficacy of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
It may reduce the therapeutic effect of gastrointestinal agents
it may decrease the levels of serum concentration of Fosfomycin
it may decrease the levels of serum concentration of Sirolimus
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
hydrocodone/chlorpheniramine/pseudoephedrine
may diminish the therapeutic effect
may diminish the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effect
may decrease the therapeutic effects of opioid agonists
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may reduce the therapeutic effect of gastrointestinal agents
may decrease the therapeutic effect of anticholinergic agents
may decrease the therapeutic effect of opioid agonists
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of anticholinergic agents
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may reduce the effect of gastrointestinal drugs
may decrease the therapeutic effect of Anticholinergic Agents
may decrease the therapeutic effect of Opioid Agonists
buprenorphine,long-acting injection
may decrease the therapeutic effect of Opioid Agonists
Gastrointestinal agents may lower the serum levels of the antibiotic fosfomycin
acetaminophen/doxylamine/dextromethorphan
may decrease the therapeutic effect of anticholinergic Agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
they decrease the efficacy of gastrointestinal agents
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
Frequency defined:
>10%
Antibody development
Myalgia
Increased creatinine phosphokinase
<1%
Anaphylaxis
Pregnancy consideration: only preferred if conventional therapies do not work to treat asthma in pregnancy.
Lactation: Vedolizumab can be excreted in breast milk.
Pregnancy category:
Patient information leaflet
Generic Name: Vedolizumab
Pronounced: ve-do-li-zu-mab
Why do we use vedolizumab?
Vedolizumab is used to treat Crohn disease and ulcerative colitis.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
